
Atish Choudhury, MD PhD
@AtishChoudhury
Followers
1K
Following
1K
Media
20
Statuses
321
Medical Oncologist Lank Center for Genitourinary Oncology @DanaFarber Views expressed herein are my own
Boston, MA
Joined September 2016
🇬🇷 Fantastic dinner at Ammos restaurant after a phenomenal Friday at . #Athensmeeting organized by.@PGrivasMDPhD with .@Prof_Nick_James, .@bergsa83, @drjefstathiou, @DrTFriedlander, @easterho. Thank you for the wonderful hospitality!
0
2
24
Thank you @urotoday and @RKSayyid for this comprehensive writeup of my talk. ADT-free strategies certainly warrant further study, but novel treatments also bring the opportunity to explore multimodality strategies with curative intent. @DanaFarber_GU @CaPsurvivorship.
#BULLSEYE Discussion: Radioligand Therapies Unplugged: Is it time to break up with androgen deprivation therapy? Presented by @AtishChoudhury @DanaFarber. #ASCO25 written coverage by @RKSayyid @USC > @ASCO
1
1
9
Thank you to the discussant Rahul Aggarwal and @jordanciuro for highlighting A-DREAM for treatment interruption for pts with PSA < 0.2 after 18-24 mo of ADT+ARPI, with primary endpoint of 18 months treatment-free with testosterone recovery. @DanaFarber_GU @bergsa83 @ALLIANCE_org.
🔎Tailoring treatment in mCSPC w/ biomarkers? Evolving landscape beyond high vs low and synchronous vs metachronous disease @ASCO . ✅PSA nadir is strongly prognostic in IRONMAN - pending trial data (TRIPLE-SWITCH and A-DREAM if PSA >/0.2) to guide nadir in therapy decisions
2
4
16
RT @DrChoueiri: 📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapies Unplugged: Is It Time to Break up With ADT? ….
0
9
0
The whole team at the Gelb Center for Translational Research @DanaFarber_GU are so proud of Ilana's poster presentation and many other achievements!.
Great job by Ilana E. presenting ctDNA data from our combined @DanaFarber_GU @MGHCancerCenter @BrighamRadOnc cohort of patients with MIBC treated with TMT! Post-treatment ctDNA status is highly prognostic in the TMT setting.
2
4
17
RT @DanaFarberNews: Prostate cancer at #ASCO25: Talazoparib + tazemetostat showed expected bone marrow suppression & limited benefit in pre….
0
4
0
We are so honored to have you join us, @FaltasLab, and we are really looking forward to your talk on this fascinating topic!.
1
0
10
RT @MikeSerzanMD: 🗣️Prostate Cancer Rapid Oral Abstracts #GU25. Dr Michael Schweizer presenting Ab138 "Mevrometostat (PF-06821497), an (EZH….
0
5
0
RT @MikeSerzanMD: 🗣️Prostate Cancer Rapid Oral Abstracts #GU25. Dr Abdenour Nabid presenting Ab310 "Impact of testosterone recovery after a….
0
8
0
So proud for Autumn Gagnon to have the opportunity to present her work on testosterone suppression and recovery with abiraterone after early LHRH-A discontinuation. We are excited that she has chosen to apply to medical school! @DanaFarber_GU
0
0
28
Thank you @DanaFarberNews for highlighting this work conducted by talented CRC Autumn Gagnon demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping.
Prostate cancer research at #ASCOGU25: @DanaFarber's @AtishChoudhury, MD, PhD, says there was faster testosterone recovery for patients stopping hormone therapy early while using it with abiraterone acetate and prednisone. Learn more in this video:
0
0
6
Thank you @DanaFarber for this recognition, and to @DrChoueiri for your guidance and advocacy. I appreciate all the support from mentors, collaborators, colleagues, research staff, and trial participants as we try to continue to advance care of patients with GU cancers.
Congratulations to @DanaFarber_GU Dr. @AtishChoudhury for his prestigious George Canellos Excellence in Clinical Investigation @DanaFarber !!. @DanaFarberNews @harvardmed
8
3
71
Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion.
Thank you to @NCCN, @SumitomoPharma, @PfizerOncMed, @BayerOncMed for supporting our study entitled Comeback from Long CoursE ADT with RElugolix and Darolutamide (CLEARED), testing T recovery (and exploring QOL and PK) with 2 years of this combination in HSPC. @DanaFarber_GU.
1
2
10
It's not too late to join our contribute to our team at to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources.
us.movember.com
Movember, the month formerly known as November, is a moustache growing charity event held during November each year that raises funds and awareness for men's health.
0
1
3
See you at Kings Back Bay on Monday 11/25/24 from 6-10 pm for BellissiMO’s @Movember Fundraising Finale. There will be food, karaoke, and celebration! .@DrPaulNguyen @RickLee6 @AFeldmanMD.@loreleimucci @mishabeltran @MA_Preston @qdtrinh @sophia_kamran @BoyajianRichard.
1
1
7
Congratulations to @PrafulRavi1 and colleagues for presenting data from our cohort. Of note, 3-year cPFS after T recovery for patients receiving "total therapy" was 51% for those who received >=12 mo ADT, and the swimmer's plot shows patients out to > 10 years after T recovery.
Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in @EurUrolOncol:.
1
2
15
RT @PrafulRavi1: Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-d….
0
22
0
RT @AarmstrongDuke: Great job @DRathkopf @myESMO presenting on our new AR degrader! Now published in @Annals_Oncology for more details: htt….
0
11
0
I am so appreciative that my dear patient Adam was willing to come out to Fenway Park for the @WEEI / @NESN @TheJimmyFund Radio-Telethon on his wedding anniversary (!) to raise awareness around testicular cancer and to support research at @DanaFarber @DanaFarber_GU. #KCANCER.
Jones & Mego: Adam Reczkowski, 41, testicular cancer, Dedham, and Atish Choudhury, MD, PhD, Clinical Investigator in the Lank Center for Genitourinary Oncology, and Chair of the Gelb Center for Translational Research, Instructor in Medicine, Dana-Farber
1
1
16